Alpine Immune Sciences Overview
- Year Founded
-
2007

- Status
-
Private
- Employees
-
142

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$4.9B
Alpine Immune Sciences General Information
Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Contact Information
Website
www.alpineimmunesciences.comCorporate Office
- 188 East Blaine Street
- Suite 200
- Seattle, WA 98102
- United States
Corporate Office
- 188 East Blaine Street
- Suite 200
- Seattle, WA 98102
- United States
Alpine Immune Sciences Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
11. Merger/Acquisition | 20-Apr-2024 | $4.9B | Completed | Generating Revenue | ||
10. 2PO | 06-Nov-2023 | Completed | Generating Revenue | |||
9. 2PO | 21-Sep-2022 | Completed | Generating Revenue | |||
8. PIPE | 14-Sep-2021 | Completed | Generating Revenue | |||
7. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
6. PIPE | 24-Jul-2020 | Completed | Generating Revenue | |||
5. PIPE | 18-Jan-2019 | Completed | Generating Revenue | |||
4. Reverse Merger | 18-Apr-2017 | Completed | Generating Revenue | |||
3. Later Stage VC | 01-Apr-2017 | $17M | $66.3M | Completed | Generating Revenue | |
2. Early Stage VC (Series A2) | 13-Jun-2016 | $48M | $49.3M | Completed | Generating Revenue |
Alpine Immune Sciences Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A2 | ||||||||
Series A1 | ||||||||
Seed | 5,000,000 | $0.000100 | 6% | $0.25 | $0.25 | 1x | $0.25 | 17.56% |
Alpine Immune Sciences Comparisons
Industry
Financing
Details
Alpine Immune Sciences Competitors (9)
One of Alpine Immune Sciences’s 9 competitors is Regeneron Pharmaceuticals, a Formerly VC-backed company based in Tarrytown, NY.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
Vera Therapeutics | Formerly VC-backed | Brisbane, CA | ||||
Shattuck Labs | Formerly VC-backed | Austin, TX | ||||
Xencor | Formerly VC-backed | Pasadena, CA | ||||
Zymeworks | Formerly VC-backed | Vancouver, Canada |
Alpine Immune Sciences Patents
Alpine Immune Sciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4490173-A1 | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses | Pending | 07-Mar-2022 | ||
CA-3216795-A1 | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein | Pending | 07-May-2021 | ||
AU-2022269139-A1 | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein | Pending | 07-May-2021 | ||
EP-4333869-A1 | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein | Pending | 07-May-2021 | ||
US-20240279310-A1 | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein | Pending | 07-May-2021 | C07K14/70578 |
Alpine Immune Sciences Signals
Alpine Immune Sciences Acquisitions (1)
Alpine Immune Sciences’s most recent deal was a Merger/Acquisition with Nivalis Therapeutics for . The deal was made on 24-Jul-2017.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Nivalis Therapeutics | 24-Jul-2017 | Merger/Acquisition | Biotechnology |
Alpine Immune Sciences ESG
Risk Overview
Risk Rating
Updated January, 10, 2023
29.73 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

Alpine Immune Sciences FAQs
-
When was Alpine Immune Sciences founded?
Alpine Immune Sciences was founded in 2007.
-
Where is Alpine Immune Sciences headquartered?
Alpine Immune Sciences is headquartered in Seattle, WA.
-
What is the size of Alpine Immune Sciences?
Alpine Immune Sciences has 142 total employees.
-
What industry is Alpine Immune Sciences in?
Alpine Immune Sciences’s primary industry is Pharmaceuticals.
-
Is Alpine Immune Sciences a private or public company?
Alpine Immune Sciences is a Private company.
-
What is the current valuation of Alpine Immune Sciences?
The current valuation of Alpine Immune Sciences is
. -
What is Alpine Immune Sciences’s current revenue?
The current revenue for Alpine Immune Sciences is
. -
How much funding has Alpine Immune Sciences raised over time?
Alpine Immune Sciences has raised $508M.
-
Who are Alpine Immune Sciences’s competitors?
Regeneron Pharmaceuticals, Vera Therapeutics, Shattuck Labs, Xencor, and Zymeworks are some of the 9 competitors of Alpine Immune Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »